Canaccord Genuity reissued their buy rating on shares of Exact Sciences Corporation (NASDAQ:EXAS) in a research report sent to investors on Tuesday, Marketbeat.com reports. Canaccord Genuity currently has a $60.00 price target on the medical research company’s stock, up from their prior price target of $45.00.

Other equities analysts have also recently issued research reports about the company. Craig Hallum upped their target price on Exact Sciences Corporation from $35.00 to $41.00 in a report on Friday, July 7th. Benchmark Co. set a $50.00 target price on Exact Sciences Corporation and gave the stock a buy rating in a report on Friday, July 7th. BTIG Research reaffirmed a buy rating and issued a $45.00 target price (up previously from $35.00) on shares of Exact Sciences Corporation in a report on Monday, July 17th. BidaskClub raised Exact Sciences Corporation from a hold rating to a buy rating in a report on Thursday, June 22nd. Finally, Vetr cut Exact Sciences Corporation from a strong-buy rating to a buy rating and set a $37.46 target price for the company. in a report on Monday, June 19th. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $43.11.

Shares of Exact Sciences Corporation (NASDAQ EXAS) traded up 1.27% during mid-day trading on Tuesday, hitting $48.74. The stock had a trading volume of 763,936 shares. The stock’s 50-day moving average price is $43.08 and its 200 day moving average price is $34.95. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $50.65. The company’s market capitalization is $5.80 billion.

Exact Sciences Corporation (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. The company had revenue of $57.65 million during the quarter, compared to analysts’ expectations of $47.73 million. On average, analysts predict that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

WARNING: “Canaccord Genuity Reaffirms Buy Rating for Exact Sciences Corporation (EXAS)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/10/06/canaccord-genuity-reaffirms-buy-rating-for-exact-sciences-corporation-exas.html.

In other news, SVP D Scott Coward sold 29,115 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $47.16, for a total value of $1,373,063.40. Following the completion of the sale, the senior vice president now owns 64,991 shares of the company’s stock, valued at $3,064,975.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Thomas D. Carey purchased 2,500 shares of the firm’s stock in a transaction dated Thursday, August 17th. The stock was bought at an average cost of $37.71 per share, with a total value of $94,275.00. Following the purchase, the director now owns 60,858 shares of the company’s stock, valued at approximately $2,294,955.18. The disclosure for this purchase can be found here. In the last three months, insiders sold 237,444 shares of company stock valued at $10,412,421. Insiders own 4.00% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Exact Sciences Corporation by 8.0% in the second quarter. Vanguard Group Inc. now owns 9,459,679 shares of the medical research company’s stock valued at $334,589,000 after buying an additional 700,051 shares during the period. BlackRock Inc. boosted its position in shares of Exact Sciences Corporation by 1.2% during the 2nd quarter. BlackRock Inc. now owns 6,884,886 shares of the medical research company’s stock valued at $243,518,000 after purchasing an additional 80,589 shares in the last quarter. Point72 Asset Management L.P. boosted its position in shares of Exact Sciences Corporation by 1,534.3% during the 1st quarter. Point72 Asset Management L.P. now owns 2,500,476 shares of the medical research company’s stock valued at $59,061,000 after purchasing an additional 2,347,476 shares in the last quarter. Fred Alger Management Inc. bought a new stake in shares of Exact Sciences Corporation during the 2nd quarter valued at about $84,177,000. Finally, Lord Abbett & CO. LLC boosted its position in shares of Exact Sciences Corporation by 59.1% during the 2nd quarter. Lord Abbett & CO. LLC now owns 2,356,706 shares of the medical research company’s stock valued at $83,357,000 after purchasing an additional 875,527 shares in the last quarter. 85.23% of the stock is owned by institutional investors.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Analyst Recommendations for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.